{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:33:05Z","timestamp":1787776385876,"version":"build-2784847793"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Allergic rhinitis (AR) is a type 1 allergic disease of the nasal mucosa, characterized by paroxysmal repetitive sneezing, watery rhinorrhea, and nasal blockage with the prevalence of 25% worldwide. Bilastine is a newer second-generation H1 antihistaminic approved for the symptomatic treatment of AR and chronic urticaria in patients older than 12 years. To date, there are very few studies in the Indian population comparing the efficacy, safety, and its effect on cognition of bilastine with second-generation antihistaminics. Hence, the study was planned to assess and compare the efficacy, tolerability, and the effect on cognition of cetirizine and bilastine in patients of AR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The aim is to assess and compare the efficacy and tolerability of cetirizine and bilastine in patients with AR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>It was a randomized, open-label, parallel-group, comparative study conducted on 80 patients of AR attending the ENT outpatient department of a tertiary care teaching hospital. Patients were divided into two groups of 40 each. They received either cetirizine 10 mg or bilastine 20 mg once daily for 2 weeks, and efficacy and tolerability were assessed at 2 weeks follow-up visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The difference in mean total symptom score was significant in bilastine as well as cetirizine, which showed that bilastine was equally efficacious as cetirizine. Adverse events were reported more in the cetirizine group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Bilastine is equally efficacious as cetirizine and a favorable tolerability profile may make it a more tolerable H1-antihistaminic than cetirizine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/picr.picr_164_24","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T10:09:21Z","timestamp":1748513361000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A comparative study of efficacy and tolerability of cetirizine and bilastine in patients of allergic rhinitis: An open-label, randomized, parallel-group study"],"prefix":"10.4103","author":[{"given":"Sneha P.","family":"Pawar","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punam A.","family":"Gosavi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrunalini Vinay","family":"Kalikar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"R1-20250529","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.18203\/2319-2003.ijbcp20194276","article-title":"A comparative study to assess the efficacy and safety of bepotastine and cetirizine in allergic rhinitis","volume":"8","author":"Priyanka","year":"2019","journal-title":"Int J Basic Clin Pharmacol"},{"key":"R2-20250529","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(11)60130-X","article-title":"Allergic rhinitis","volume":"378","author":"Greiner","year":"2011","journal-title":"Lancet"},{"issue":"Suppl 1","key":"R3-20250529","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.2500\/aap.2012.33.3603","article-title":"Burden of allergic rhinitis: Allergies in America, Latin America, and Asia-Pacific adult surveys","volume":"33","author":"Meltzer","year":"2012","journal-title":"Allergy Asthma Proc"},{"issue":"Suppl 85","key":"R4-20250529","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1398-9995.2007.01549.x","article-title":"A survey of the burden of allergic rhinitis in Europe","volume":"62","author":"Canonica","year":"2007","journal-title":"Allergy"},{"key":"R5-20250529","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1046\/j.1365-2745.2002.01483.x","article-title":"Relationship between allergic rhinitis, disturbed cognitiv functions and psychological well-being: Allergic rhinitis and cognitive functions","volume":"32","author":"Kremer","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"R6-20250529","doi-asserted-by":"crossref","first-page":"S763","DOI":"10.1016\/S0091-6749(97)70125-8","article-title":"Pathogenesis of allergic rhinitis","volume":"99","author":"Baraniuk","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"R7-20250529","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13223-018-0280-7","article-title":"Allergic rhinitis","volume":"14","author":"Small","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R8-20250529","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/j.1365-2222.2009.03257.x","article-title":"Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: A randomized, double-blind, parallel-group study","volume":"39","author":"Kuna","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"R9-20250529","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/00003495-200464050-00008","article-title":"Cetirizine: A review of its use in allergic disorders","volume":"64","author":"Curran","year":"2004","journal-title":"Drugs"},{"key":"R10-20250529","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12948-015-0008-x","article-title":"Bilastine: New insight into antihistamine treatment","volume":"13","author":"Ridolo","year":"2015","journal-title":"Clin Mol Allergy"},{"key":"R11-20250529","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/ijdd.ijdd_12_18","article-title":"Bilastine: A novel antihistamine","volume":"4","author":"Godse","year":"2018","journal-title":"Indian J Drugs Dermatol"},{"key":"R12-20250529","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000346845","article-title":"Reliability, validity, and optimal cutoff score of the Montreal cognitive assessment (Changsha version) in ischemic cerebrovascular disease patients of Hunan province, China","volume":"3","author":"Tu","year":"2013","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"R13-20250529","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","article-title":"Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease","volume":"73","author":"Hoops","year":"2009","journal-title":"Neurology"},{"key":"R14-20250529","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13223-015-0082-0","article-title":"The allergic rhinitis \u2013 Clinical investigator collaborative (AR-CIC): Nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies","volume":"11","author":"Ellis","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R15-20250529","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.2500\/ar.2013.4.0065","article-title":"Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis","volume":"4","author":"Aneeza","year":"2013","journal-title":"Allergy Rhinol (Providence)"},{"key":"R16-20250529","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/cea.12121","article-title":"Visual analogue scale in patients treated for allergic rhinitis: An observational prospective study in primary care: Asthma and rhinitis","volume":"43","author":"Demoly","year":"2013","journal-title":"Clin Exp Allergy"},{"issue":"Suppl 86","key":"R17-20250529","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2) LEN and AllerGen)","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"R18-20250529","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jaci.2012.07.053","article-title":"Allergic rhinitis and its impact on asthma (ARIA): Achievements in 10 years and future needs","volume":"130","author":"Bousquet","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R19-20250529","first-page":"1","article-title":"Local and systemic safety of intranasal corticosteroids","volume":"22","author":"Sastre","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R20-20250529","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.anai.2009.11.020","article-title":"Evaluating approved medications to treat allergic rhinitis in the United States: An evidence-based review of efficacy for nasal symptoms by class","volume":"104","author":"Benninger","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R21-20250529","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1398-9995.2008.01813.x","article-title":"Comparison of the efficacy and safety of bilastine 20 mg versus desloratadine 5 mg in seasonal allergic rhinitis patients","volume":"64","author":"Bachert","year":"2009","journal-title":"Allergy"},{"key":"R22-20250529","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jaci.2010.06.034","article-title":"Uncontrolled allergic rhinitis during treatment and its impact on quality of life: A cluster randomized trial","volume":"126","author":"Bousquet","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R23-20250529","first-page":"245","article-title":"Comparison of cetirizine and bilastine in the treatment of allergic rhinitis","volume":"117","author":"Smith","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R24-20250529","first-page":"89","article-title":"Cognitive and sedative effects of cetirizine and bilastine in patients with allergic rhinitis","volume":"41","author":"Jones","year":"2019","journal-title":"Int J Clin Pharmacol"},{"key":"R25-20250529","first-page":"269","article-title":"Differential effects of cetirizine and bilastine on cognitive function and psychomotor performance","volume":"58","author":"Farr\u00e9","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"R26-20250529","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14740338.2018.1502268","article-title":"Comparative study of the effect of bilastine and cetirizine on cognitive functions at ground level and at an altitude of 4,000 m simulated in hypobaric chamber: A randomized, double-blind, placebo-controlled, cross-over study","volume":"17","author":"Rem\u00e9nyi","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"R27-20250529","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.2174\/1389557521666210520171457","article-title":"Chemistry, pharmacokinetics, pharmacodynamics and analytical methods of bilastine, a histamine H1 receptor antagonist: An update","volume":"21","author":"Sharma","year":"2021","journal-title":"Mini Rev Med Chem"}],"container-title":["Perspectives in Clinical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.picr_164_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:09:38Z","timestamp":1787774978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.picr_164_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":27,"URL":"https:\/\/doi.org\/10.4103\/picr.picr_164_24","relation":{},"ISSN":["2229-3485","2229-5488"],"issn-type":[{"value":"2229-3485","type":"print"},{"value":"2229-5488","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"2024-09-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}